Literature DB >> 15907352

Interferon-induced depression: strategies in treatment.

Gregory M Asnis1, Richard De La Garza.   

Abstract

Interferon (IFN) is a pro-inflammatory cytokine that is widely used for the treatment of a number of disorders including viral infections, hematological proliferative disorders, and skin malignancies. Unfortunately, IFN frequently induced depression and has led to compromised tolerability with lowering of the dose of IFN and even discontinuation of treatment. Thus, it is imperative to diagnose IFN-induced depression early, evaluate whether this depression is associated with IFN-induced anemia or thyroid dysfunction, which can be corrected, and if necessary treat with antidepressants. IFN-induced depression is highly responsive to antidepressants with benefits occurring frequently at relatively low doses and after only a few weeks. Although SSRIs have mainly been studied, non-SSRIs appear to be effective also. Antidepressants have a number of risks and side effects that must be considered and may enter into the decision as to which antidepressant to choose. If IFN induces a depression in a patient with a bipolar disorder history, antidepressant treatment must include a mood stabilizer. In the case of vulnerable patients (e.g., those who have significant depressive symptoms prior to IFN or who have had an IFN-induced depression in the past) prophylactic antidepressant treatment appears to decrease the likelihood of having an IFN-induced depression. On the basis of known and effective treatment strategies, IFN-induced depression should not be an obstacle for continued treatment in most patient populations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907352     DOI: 10.1016/j.pnpbp.2005.03.006

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  15 in total

1.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

Review 2.  Mood disorders and obesity: understanding inflammation as a pathophysiological nexus.

Authors:  Joanna K Soczynska; Sidney H Kennedy; Hanna O Woldeyohannes; Samantha S Liauw; Mohammad Alsuwaidan; Christina Y Yim; Roger S McIntyre
Journal:  Neuromolecular Med       Date:  2010-12-17       Impact factor: 3.843

3.  Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid β plaques.

Authors:  Ethan R Roy; Gabriel Chiu; Sanming Li; Nicholas E Propson; Rupa Kanchi; Baiping Wang; Cristian Coarfa; Hui Zheng; Wei Cao
Journal:  Immunity       Date:  2022-04-19       Impact factor: 43.474

Review 4.  Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.

Authors:  Mitchell L Shiffman
Journal:  Curr Gastroenterol Rep       Date:  2006-02

5.  Management of depression induced by interferon hepatitis therapies.

Authors:  Hema Shah; Snehal Kadia; Radhika Bawa; Steven Lippmann
Journal:  Prim Care Companion CNS Disord       Date:  2013-09-05

Review 6.  Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review.

Authors:  Arne Schäfer; Hans-Ulrich Wittchen; Jochen Seufert; Michael R Kraus
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035

7.  The gut microbiome regulates the increases in depressive-type behaviors and in inflammatory processes in the ventral hippocampus of stress vulnerable rats.

Authors:  Jiah Pearson-Leary; Chunyu Zhao; Kyle Bittinger; Darrell Eacret; Sandra Luz; Abigail S Vigderman; Gabriel Dayanim; Seema Bhatnagar
Journal:  Mol Psychiatry       Date:  2019-03-04       Impact factor: 15.992

Review 8.  The common denominators of sleep, obesity, and psychopathology.

Authors:  Andrew S Tubbs; Waliuddin Khader; Fabian Fernandez; Michael A Grandner
Journal:  Curr Opin Psychol       Date:  2019-12-02

9.  Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study.

Authors:  Wei-Chun Chen; Hsueh-Chou Lai; Wen-Pang Su; Mahalakshmi Palani; Kuan-Pin Su
Journal:  Psychiatry Investig       Date:  2015-01-12       Impact factor: 2.505

Review 10.  Interferon-induced depression in hepatitis C: an update.

Authors:  Brian Keefe
Journal:  Curr Psychiatry Rep       Date:  2007-06       Impact factor: 8.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.